

CPIPS 2019

4th China Pharma IP Summit 2019 (Conference Review)

医药IP人年度盛会

Annual Event in China for Global Pharma IPers



CPIPS Conference Photo Live



CPIPS Official Wechat Account

56 Distinguished Speakers



Qingkui Zhang
Honorary Director
Pharma IP Research Committee
of Chinese Pharma Association



Yongshun Cheng
Director
Beijing Intellectual
Property Institute



Joerg Thomaier
Head Of IP
Bayer Group



Christof Bull
Associate General Patent
Counsel
UCB Biopharma



Michael J. Wise
Partner
Perkins Coie LLP



Toru Matsuoka
Deputy Director
Examination Standards
Office, JPO



Peter L. Dolan
Strategy and Business
Development Senior Director
Sanofi



Feng Xu
IP Director for China and Asia
AstraZeneca



Poonam Raghuvanshi
Vice President & Head of IP
Dr. Reddy's Laboratories



Wenping Chen
Partner
King & Wood Mallesons



Tina Tai
Partner
King & Wood Mallesons



Ilseok Alban Kang
Patent Attorney
FirstLaw P. C.



Wu Li
Partner
Anjie Law Firm



Carl A. Morales
Partner
Dechert LLP



Gang Wang
Associate
Dechert LLP



Yang Xu
Patent Attorney
BeiGene, Ltd.



Daisy Wu
IP Director
Shanghai Henlius
Biotech, Inc.



Gustavo Morais
Partner
Dannemann Siemsen



Ana Carneiro
Partner
Dannemann Siemsen



Yongfeng Zheng
Legal Director and Vice
President of Research Institute
Tasly Holding Group



Teresa A. Lavoie
Principal
Fish & Richardson P.C.



Andy Zhang
Senior Corporate Counsel
Intellectual Property
Sunovion Pharmaceutical



Wenjun Geng
IP Director
CHIA TAI TIANQING



Chris Goddard
Partner
Dehns Patent and Trade
Mark Attorneys



Lifang Sun
IP Vice President
Luye Pharma Group



Nick Qinghui Liu
Partner
Anjie Law Firm



Caihui Li
Senior IP Director
3SBio Group



Xiarui Dou
IP and Legal Director
Yabao Pharmaceutical
Group



Xiangjun Li
Vice President
SHIJIAZHANG YILING
PHARMACEUTICAL



Qiujuan Ma
Director of
Pharmaceutical Division
Patent Examination
Cooperation Beijing Center



Yuanxia Liu
Founding Partner
Beijing Origintelligence
Intellectual Property
Law Firm



Yite John Lu
Partner
Milbank LLP



Peter Storm
Senior Patent Attorney
AstraZeneca



Lareina Chen
IP Manager
Shanghai Junshi
Biosciences



Wanli Tang
Associate
Jones Day



Jiwei Yin
Partner,
Deputy General Manager
Beijing Sino-Creativity
Intellectual Property



Xiaoting Song
Professor
Shanghai International
School of Intellectual
Property of Tongji University



Yehudah Livneh
Former General Patent
Counsel
Teva Pharmaceuticals



Mahendra B. Thakre
Senior General Manager
Mylan Laboratories



Hou Yao
Researcher of Chemistry
Appeal Dept I
Reexamination and Invalidation
Department of the Patent Office
CNIPA



Jiangming Wu
Deputy Director
Patent Examination
Cooperation Jiangsu Center of
The Patent Office



Richard Liu
Partner
SAELINK LAW



Alexander Jamnišek
Senior Patent Attorney
Sandoz



Bharati Nadkarni
Vice President Portfolio
Planning and IP litigation
Sun Pharmaceutical



Markus Engelhard
Partner
Boehmert & Boehmert



Jincai Hou
Research Institute
President
China Shineway
Pharmaceutical Group



Shashank Upadhye
Partner
Upadhye Cwik LLP



Christopher T. Griffith
Founding Partner
Green, Griffith
& Borg-Breen LLP



Shuyin Zhu
Senior Consultant
Lee and Li
Attorneys-at-Law



Tony Chen
Partner
Jones Day



Lijuan Wu
Deputy Director
Beijing Intellectual
Property Institute



Ian Washburn
Partner
Irell & Manella LLP



Jun Yi
Head of Case-filing
Division
Beijing Intellectual
Property Court



Bo Xu
Counsel
LUNG TIN LAW FIRM
Former Judge of Beijing Intellectual
Property Court



Keith A. Orso
Partner
Irell & Manella LLP



Chenglong Ma
Managing Partner Shanghai
Office
HENGDU LAW FIRM

..... Organizer


..... Supporting Partner




As an annual event dedicated to pharmaceutical intellectual property, 4th China Pharma IP Summit 2019 (CPIPS2019) was successfully held at Primus Hotel Shanghai Hongqiao China on 23rd -25th , Oct with a record-breaking over **540 attendees** from **global and china local pharma/biotech companies, law firms, IP agencies, IP solution providers**, and over 56 speakers given presentation. CPIPS 2019, themed as “Pharma IP Challenges and Opportunities for Global Pharma Innovation” topics covered the global IP Landscape and hot issues in patent prosecution, patent examination rules and comparison in different jurisdictions include mainly **China, Europe, US, Japan, South Korea, India and Brazil**. And compare to past three years, CPIPS 2019 given half day discussion on patent prosecution of Traditional Chinese Medicine and Challenges of Going Out “

CPIPS 2019 : IP Challenges & Opportunities for Global Pharma Innovation

Oct 23rd:	Focus on China: IP Reform in China (Patent Linkage,Regulatory Data Protection,Patent Term Restoration),Patent Examination Practices (Data Supplementation, Compound Inventions,Biological Sequences) and Challenges ,Opportunities for Generic and Innovators under New Environment in China
Oct 24th AM:	Focus On US: Patent Layout, Inter Party Review, Generic Drug Launches, Biosimilar Patent Litigation and IP Strategy in US
Oct 24th PM:	Focus on Europe: Updates and Implication of Brexit, Unitary Patent & UPC and Patent Land-scape of Global Antibodies
Oct 25th AM:	Focus on Japan, India, South Korea and Brazil: IP System, Patent Examination Practices, Case Studies of India Generic Com-pany
Oct 25th PM:	Focus on Traditional Chinese Medicine: Patenting Situation & Creative Evaluation for TCM, IP Challenges and Opportu-nities of Going out



Trends of Participants Number



Company Category



Group Photo of Pharma IP Right Research Committee of Chinese Pharmaceutical Association Members

This year's distinguished speaker gathers not only officials from National IP Offices, well-known IP experts and law firms, but also IP executives and researchers of leading Pharma companies from both Generic and Innovators, including Reexamination and Invalidation Department of the Patent Office, Jones Day, Beijing Intellectual Property Institute, BeiGene, CHIA TAI TIANQING, Luye Pharma Group, AstraZeneca, Beijing Intellectual Property Court, King & Wood Mallesons, Perkins Coie LLP, 3SBio Group, Sunovion Pharmaceutical, Sun Pharmaceutical, Boehmert & Boehmert, Sanofi, Junshi Biosciences, UCB Biopharma, Shanghai Henlius Biotech, Sandoz, Japan Patent Office, Dr. Reddy's Laboratories, Dannemann Siemsen, Bayer Group, Tasly Holding Group, China Shineway Pharmaceutical Group, YILING PHARMACEUTICAL, Yabao Pharmaceutical and etc., Were all involved in very constructive and productive discussions over the balance between patent protection and public health, domestic and international patent rules, litigation, invalidation, challenges and the future trends from a variety of perspectives.

Co-Chairs



(Qingkui Zhang, Pharma IP Research Committee of Chinese Pharma Association)



(Tony Chen, Jones Day)



(Wu Li, Anjie Law Firm)



(Markus Engelhard, Boehmert & Boehmert)



(Mahendra B. Thakre, Mylan Laboratories)



(Xiaoting Song, Shanghai International School of Intellectual Property of Tongji University)

Keynot and Panel Speakers



(Yongshun Cheng, Beijing Intellectual Property Institute)



(Feng Xu, AstraZeneca)



(Yuanxia Liu, Beijing Origintelligence Intellectual Property Law Firm)



(Hou Yao, Reexamination and Invalidation Department of the Patent Office CNIPA)



(Jun Yi, Beijing Intellectual Property Court)



(Lifang Sun, Luye Pharma Group)



(Wenjun Geng, CHIA TAI TIANQING)



(Shashank Upadhye, Upadhye Cwik LLP)



(Carl A. Morales, Dechert LLP)



(Keith A. Orso, Irell & Manella LLP)



(Joerg Thomaier, Bayer Group)



(Peter L. Dolan, Sanofi)



Implication & Development of Patent Linkage, Patent Term Restoration and Regulatory Data Protection in China

(Yongshun Cheng, Yang Xu, Tony Chen, Wenjun Geng, Lifang Sun)



Identification and Persuasion Strategy of Technical Facts in Pharma Patent Cases

(Jun Yi, Feng Xu, Nick Qinghui Liu, Bo Xu, Richard Liu)



Evaluation of Inventive Step of Pharmaceutical Compound Inventions

(Tina Tai, Peter Storm, Jun Yi, Yang Xu, Wenping Chen)



IP Considerations & Strategies for Pharma Companies When Entering the U.S. Market

(Wu Li, Teresa A. Lavoie, Bharati Nadkarni, Andy Zhang, Caihui Li)



Global Patent Issues of Therapeutic Antibodies

(Wanli Tang, Markus Engelhard, Yite John Lu, Qiujuan Ma, Lareina Chen)



Best Practices for IP Litigation

(Joerg Thomaier, Shashank Upadhye, Mahendra B. Thakre, Bharati Nadkarni)



Biosimilars in US, EU and China: Where Are We Now and Where Are We Going?

(Christof Bull, Christopher T. Griffith, Caihui Li, Daisy Wu, Alexander Jamnišek)



IP Challenges and Strategy for Traditional Chinese Medicine 'Going Out'

(Xiarui Dou, Yongfeng Zheng, Caihui Li, Xiaoting Song, Jincan Hou, Xiangjun Li)



In recent years, the development of a series of ip policies in China has attracted the attention of domestic and foreign pharmaceutical enterprises, mainly including **patent term extension, patent linkage, experimental data protection, etc.** How do domestic and foreign enterprises evaluate these systems and it's implication to industry?

China IP Magazine and Managing Intellectual Property as CPIPS Meida Partner did few interviews on these relevant issues during the conference.

- Feng Xu, (IP Director for China and Asia, AstraZeneca)
- Joerg Thomaier (Head of IP, Bayer Group)
- Poonam Raghuvanshi (Vice President & Head of IP, Dr. Reddy's Laboratories)
- Michael Wise (Partner, Perkins Coie LLP)



(1300 Square meters meeting room with nearly 600 seats)



(Guest queue up to register)



(13 booths outside the conference room, Warm exchange and interaction with guest)



Every day, the conference starts from 8:30 to 6:00 p.m.,
and the guests in the conference room listen carefully and take notes



Each speaker has 5-10 minutes of Q & A interaction, and the guests actively ask questions


CPIPS 2019 Tea Break & Cocktail



(Tea Break)



(Cocktail)



Rich snacks, fruits, coffee and tea for each participant during the break time. and at the end of each day conference, cocktail party is available for all guests to communicate.

CPIPS 2019 Group photo

Guests took pictures In meeting room and outside (during the tea break, cocktail party and signature wall)



(Conference Hall)



(Signature wall)

Thanks to CPIPS 2019 Sponsors

Associate Sponsor
联席赞助



Presentation Sponsor
演讲赞助



Exhibition Sponsor
展台赞助



Green Griffith
Intellectual Property Law



Panel Discussion Sponsor
小组讨论赞助



Exclusive Sponsor
独家赞助



颈带/Lanyard



资料袋/Delegate Bag

Insertion Sponsor
插页赞助



See you at CPIPS 2020

Registration

🌐 URL: www.pharmaip.cn

✉ Mail: info@yipevents.com

☎ Tel: 021-61421082



Johnson



Eric

Sponsorship Opportunities

“ When asked which advertising mediums are most important to meeting your company's key marketing objectives today? 45 percent said conferences and events.”

---"The Economist magazine's Global CMO report"

For more information please contact us at:

Shanghai YIP Events

info@yipevents.com